Sci-Tech Seattle
SEE OTHER BRANDS

Your best source on science and technology news from Washington state

Sci-Tech Seattle: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Seattle.

Press releases published on June 4, 2025

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial …

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market Evaluation of AZD5658 expands Conduit’s …

ClarityCut AI Unveils New Creative Engine for Branded Video Production

ClarityCut AI Unveils New Creative Engine for Branded Video Production

SEATTLE, June 04, 2025 (GLOBE NEWSWIRE) -- CLEANZONE HVAC LLC has introduced the next evolution of video creation with the latest update to its AI-powered platform, ClarityCut AI. Designed for content creators, educators, and digital marketers, ClarityCut …

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by …

FOXO TECHNOLOGIES INC. COMPLETES EQUITY FUNDING AGREEMENT

FOXO TECHNOLOGIES INC. COMPLETES EQUITY FUNDING AGREEMENT

WEST PALM BEACH, FLORIDA, June 04, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that it has executed an agreement to issue 1,650 of its Series A Cumulative Convertible Redeemable Preferred …

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer …

Salsify Launches FeedbackIQ to Streamline GDSN with AI

Salsify Launches FeedbackIQ to Streamline GDSN with AI

BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Salsify, the Product Experience Management (PXM) platform empowering brand manufacturers, distributors, and retailers to win on the digital shelf, today announced a significant enhancement to its Global Data …

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors Previous clinical proof-of concept data2 for targeting HER-2 …

Melissa’s Azure Integration of SSIS Components Extends Data Quality to the Cloud

Melissa’s Azure Integration of SSIS Components Extends Data Quality to the Cloud

RANCHO SANTA MARGARITA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- As more enterprises migrate to the cloud in pursuit of scalability, speed, and simplified infrastructure, data quality often remains a bottleneck or development challenge. In response, …

Elicio Therapeutics Secures $10 Million in Financing

Elicio Therapeutics Secures $10 Million in Financing

Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage …

Repeat: Rocket Doctor, a Treatment.com AI company, Joins Larta Institute’s 2025 Heal.LA Accelerator Cohort to Expand Access to Virtual Care

Repeat: Rocket Doctor, a Treatment.com AI company, Joins Larta Institute’s 2025 Heal.LA Accelerator Cohort to Expand Access to Virtual Care

One of 15 companies selected across critical areas including chronic disease, women’s health, and mental health. Program provides mentorship, regulatory guidance, and funding access to help scale solutions that improve care access and equity. Rocket Doctor …

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society …

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, June 04 …

AgEagle Aerial Systems Secures International Sale of eBee VISION Drones to Paraguayan Government

AgEagle Aerial Systems Secures International Sale of eBee VISION Drones to Paraguayan Government

Strategic Latin American Deal Expands AgEagle’s Global UAS Presence WICHITA, Kan., June 04, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS), a leading provider of advanced drone and aerial imaging solutions, announces the sale of two eBee …

Global Technologies, LTD Announces Strategic Pivot and New Agreements in Health & Wellness Sector

Global Technologies, LTD Announces Strategic Pivot and New Agreements in Health & Wellness Sector

Greensboro, NC, June 04, 2025 (GLOBE NEWSWIRE) -- Global Technologies, LTD (OTCPK: GTLL), a public, multi-operational company focused on innovation in health and wellness, recently announced corporate developments and commercial milestones signaling a bold …

reAlpha Appoints Mike Logozzo as CEO to Accelerate Growth

reAlpha Appoints Mike Logozzo as CEO to Accelerate Growth

DUBLIN, Ohio, June 04, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq: AIRE) (“reAlpha” or the “Company”), an AI-powered real estate technology company, today announced a strategic leadership transition to support its next phase of growth. Effective …

NobleAI Introduces Powerful, Practical AI Solutions For Chemistry and Energy

NobleAI Introduces Powerful, Practical AI Solutions For Chemistry and Energy

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- NobleAI announced today commercial availability of its best-in-class VIP (Visualizations, Insights …

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. ET. The …

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of- …

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service